Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 19/20 | 1.00 |
| ▸ | KDM1B | Q8NB78 | 19/20 | 1.00 |
| ▸ | MAOB | P27338 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.90 |
| ▸ | MAOA | P21397 | 8/20 | 0.80 |
| ▸ | HTR6 | P50406 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19725480 | 1.00 | KDM1A (1.00) | KDM1AKDM1BMAOBKCNH2MAOA | |
| SCHEMBL19725476 | 0.95 | KDM1A (1.00) | KDM1AKDM1BMAOBKCNH2MAOA | |
| SCHEMBL21114595 | 0.90 | KDM1A (0.90) | KDM1AKDM1BMAOBKCNH2MAOA | |
| SCHEMBL21156167 | 0.90 | KDM1A (0.83) | KDM1AKDM1BMAOBKCNH2MAOA | |
| SCHEMBL19725432 | 0.90 | KDM1A (0.90) | KDM1AKDM1BMAOBKCNH2MAOA | |
| SCHEMBL21114660 | 0.89 | KDM1A (1.00) | KDM1AKDM1BMAOBKCNH2MAOA | |
| SCHEMBL19725543 | 0.89 | KDM1A (1.00) | KDM1AKDM1BMAOBKCNH2MAOA | |
| SCHEMBL29682947 | 0.87 | KDM1A (0.83) | KDM1AKDM1BMAOBKCNH2MAOA | |
| SCHEMBL19725539 | 0.87 | KDM1A (0.83) | KDM1AKDM1BMAOBKCNH2MAOA | |
| SCHEMBL21114557 | 0.87 | KDM1A (0.83) | KDM1AKDM1BMAOBKCNH2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873292-B2 | Trans-indoline cyclopropylamine chemical compound, and method for preparation, pharmaceutical composition, and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-01-16 | — | — | US | claimed |
| US-20190210998-A1 | TRANS-INDOLINE CYCLOPROPYLAMINE CHEMICAL COMPOUND, AND METHOD FOR PREPARATION, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-07-11 | — | — | US | claimed |
| US-11873292-B2 | Trans-indoline cyclopropylamine chemical compound, and method for preparation, pharmaceutical composition, and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-01-16 | — | — | US | disclosed |
| CN-107459476-B | Anti-indoline cyclopropylamine compound and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-06-24 | — | — | CN | disclosed |
| US-20190210998-A1 | TRANS-INDOLINE CYCLOPROPYLAMINE CHEMICAL COMPOUND, AND METHOD FOR PREPARATION, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210998-A1 | TRANS-INDOLINE CYCLOPROPYLAMINE CHEMICAL COMPOUND, AND METHOD FOR PREPARATION, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | INMT, IDO1, TPH1 | KDM1A 5/4885KDM1B 10/4885MAOB 143/4885 |
| US-11873292-B2 | Trans-indoline cyclopropylamine chemical compound, and method for preparation, pharmaceutical composition, and use thereof | INMT, IDO1, TPH1 | KDM1A 5/4885KDM1B 10/4885MAOB 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.